Top Markets
#1 Akedo Akedo +54.06%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.26%
#4 Cross Cross +47.18%
#5 Black Phoenix Black Phoenix +34.15%
#6 Velvet Velvet +31.77%
#7 OVERTAKE OVERTAKE +18.70%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.05%
#9 Movement Movement +13.43%
#10 Perle Perle +11.98%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Nutranomics, Inc. Nutranomics, Inc.

Nutranomics, Inc.

NNRX
Rank in Stocks #38766
Nutranomics, Inc. focuses on the research, development, and marketing of... Nutranomics, Inc. focuses on the research, development, and marketing of health-focused nutritional products. Their extensive catalog features nearly 500 distinct dietary supplements, encompassing formulations of vitamins, minerals, herbal remedies, and probiotics. Beyond its product offerings, the company provides innovative services, such as its Nutritional Blood Analysis—a diagnostic tool enabling customers to observe their blood cells live on a video monitor—and the patented Assimilation Enhancing System, which is engineered to optimize nutrient absorption. Additionally, Nutranomics delivers comprehensive educational resources, including various forms of analysis, training programs, professional certifications, and group presentations, catering to both individuals and industry experts. The distribution of its products occurs globally through a network of sales representatives across North America and Asia, alongside availability in retail stores. Nutranomics, Inc. also maintains a strategic alliance with Terra-Formance, LLC. Established in 1995, the company is based in Salt Lake City, Utah.
Share Price
$0.00005
Last synced: 2026-08-13
Market Cap
$816.23K
Change (1 day)
0.00%
Change (1 year)
4,900.00%
Country
US
Trade Nutranomics, Inc. (NNRX)

Category

Healthcare
P/E ratio for Nutranomics, Inc. (NNRX)
P/E ratio as of 2026 TTM: 0
According to Nutranomics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nutranomics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 41.61 -
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.